April 3, 2023 11:39 AM EDTUpdated September 7, 06:58 PM

Vertex and CRISPR send exa-cel for FDA approval; Aridis Therapeutics axes 20% of its workforce

Tyler Patchen

News Reporter

Kyle LaHucik

Senior Reporter

Vertex and CRISPR Therapeutics have finished the BLA for its treatment exagamglogene autotemcel, or exa-cel, and will be going toward the FDA for approval. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex and CRISPR send exa-cel for FDA approval; Aridis Therapeutics axes 20% of its workforce

Tyler Patchen

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Ver­tex and CRISPR send exa-cel for FDA ap­proval; Aridis Ther­a­peu­tics ax­es 20% of its work­force

News Reporter

Senior Reporter

Sign up to read this article for free.

Vertex and CRISPR send exa-cel for FDA approval; Aridis Therapeutics axes 20% of its workforce